Showing 2637 results
- Media Release /
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of… - Media Release /Continuous Kesimpta® (ofatumumab) treatment maintained profound suppression of MRI lesion activity and resulted in an increase in the number of patients with relapsing forms of multiple sclerosis (…
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
Pagination
- ‹ Previous page
- 1
- …
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- …
- 264
- › Next page